![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Hands Cleveland Diagnostics’ Prostate Cancer Test Breakthrough Status
FDA Hands Cleveland Diagnostics’ Prostate Cancer Test Breakthrough Status
![](https://www.fdanews.com/ext/resources/test/Device_Images6/ClevelandDiagnostics_Logo.png?t=1571352997&width=430)
Cleveland Diagnostics’ IsoPSA Assay, a prostate cancer diagnostic test, has received breakthrough device designation from the FDA.
The non-invasive, blood-based assay’s accuracy is superior to traditional prostate-specific antigen (PSA) tests when detecting high-grade prostate cancer, according to published studies from multicenter prospective trials, Cleveland said.
Clinicians use an array of diagnostic tests and procedures to inform decisions about a patient’s prostate health and the risk of prostate cancer, the company noted, adding it believes the assay “has the potential to fill a major void in this space.”
Upcoming Events
-
21Oct